Cardiorenal Effects of Dapagliflozin-Valsartan in T2DM Patients, 2023-2024

245 patients with Type 2 Diabetes Mellitus and hypertension were studied in a retrospective cohort from January 2023 to December 2024. Zhengrong Zhou authored this dataset, which compares monotherapy and combination therapy outcomes over 24 weeks. The data includes blood pressure, glycemic, inflammatory, cardiac, and renal parameters.

Use Cases

• Compare blood pressure reduction efficacy based on systolic and diastolic measurements.
• Analyze glycemic control improvements based on FPG, 2hPG, and variability indices.
• Evaluate cardiac function changes based on LVEF, NT-proBNP, and echocardiographic measures.
• Assess renal outcomes based on eGFR, UACR, SCr, and BUN.
• Model treatment efficacy predictors based on multivariate analysis results.

Strengths

• Includes 245 patient records with propensity score matching to create balanced groups of 102 patients each.
• Contains a wide range of clinical measurements: blood pressure, glycemic parameters, inflammatory biomarkers, cardiac echocardiography, renal function, and fibrosis markers.
• Provides longitudinal data with outcomes assessed at baseline and after 24 weeks of treatment.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the final analyzed dataset is unknown, which may limit suitability assessment.
• Data may reflect temporal bias inherent to the single-center retrospective study design.

Provenance

Source

figshare

Collection Method

Retrospective cohort study of admitted patients.

Time Range

January 2023 to December 2024

Freshness

Last updated 2026-04-24 04:21:04; freshness should be verified.